In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
KRAS-driven lung cancers represent an aggressive form of NSCLC. In this study the authors perform an in vivo functional screening and identify GATAD2B as a driver of tumor growth and metastasis in KRAS-driven lung cancer.
Guardado en:
Autores principales: | Caitlin L. Grzeskowiak, Samrat T. Kundu, Xiulei Mo, Andrei A. Ivanov, Oksana Zagorodna, Hengyu Lu, Richard H. Chapple, Yiu Huen Tsang, Daniela Moreno, Maribel Mosqueda, Karina Eterovic, Jared J. Fradette, Sumreen Ahmad, Fengju Chen, Zechen Chong, Ken Chen, Chad J. Creighton, Haian Fu, Gordon B. Mills, Don L. Gibbons, Kenneth L. Scott |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7d3a32362fb643e9a451c28f602e01e5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins
por: Samrat T. Kundu, et al.
Publicado: (2018) -
Functional annotation of rare gene aberration drivers of pancreatic cancer
por: Yiu Huen Tsang, et al.
Publicado: (2016) -
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer
por: Roxsan Manshouri, et al.
Publicado: (2019) -
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
por: David H. Peng, et al.
Publicado: (2021) -
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020)